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ABSTRACT 
BACKGROUND  
                There has been a significant increase in number of HIV patients in 
India. Endocrinal involvement is common in these patients especially 
involvement of thyroid in the form of subclinical hypothyroidism in various 
studies. There is little data on abnormalities of thyroid function tests in newly 
diagnosed HIV patients and only few studies undertaken in India and hence  this 
study is done 
OBJECTIVE  
(1) To study thyroid function abnormalities in newly diagnosed HIV patients.  
(2) To find out relation between thyroid function abnormalities and severity of         
 illness in HIV infected patients.  
 
METHODS: Fifty patients who are diagnosed to have HIV infection according 
to National AIDS Control Organisation (NACO) March 2007, who fulfill 
inclusion and exclusion criteria who attend Coimbatore medical college hospital 
from september 2013 to february 2014 were included with consent. Data was 
collected by using pre-tested proforma meeting the objectives of the study. All 
enrolled patients were investigated for total T3, total T4, TSH. It was compared 
with HIV status, CD4 count and WHO clinical stage of HIV disease 
 
Of the 50 HIV patients, mean age was 38.84±8.34 years with 29 males. 
Of Thyroid dysfunction 60% were females. 62% -euthyroid, 38% -thyroid 
dysfunction; of them 20 % had subclinical hypothyroidism, 12% - 
hypothyroidism, 2% - hyperthyroidism and 4%-sick euthyroidism. 57.89% of  
thyroid dysfunction patients had CD4 count  <200 / µL p value 0.023 ODDS 
RATIO-.253 ( CI-.075-.853). 46.67 % of  WHO clinical stage 3 and 64.3 % of 
stage 4 patients  had thyroid dysfunction and chi square value 10.025, p value 
0.018.  57.89% of those with thyroid dysfunction had hemoglobin less than 9 
g/dl p value- 0.003 
CONCLUSION 
There is significant association between age and thyroid dysfunction and gender 
had no statistical association with thyroid abnormalities in HIV patients. 
Subclinical hypothyroidism is the commonest thyroid dysfunction in newly 
diagnosed HIV. Thyroid dysfunction increases when CD4 count is <200/µL and 
WHO clinical stages 3 or 4. Hemoglobin <9 g/dl and pallor is associated with 
thyroid dysfunction. Hence thyroid function screening may be done in newly 
diagnosed HIV patients with  –  CD4 <200/ µL or  WHO clinical stage 3 or 4 or 
if patient has  hemoglobin <9 g/dl or pallor. This screening helps in early 
recognition of thyroid abnormalities before antiretroviral therapy initiation as 
these drugs themselves induce thyroid dysfunction.  
Key words – HIV, thyroid dyfunction, subclinical hypothyroidism, CD4, WHO 
clinical stage, hemoglobin. 
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INTRODUCTION 
The AIDS- Acquired immunodeficiency syndrome was first 
reported in 1981.The etiologic virus Human immunodeficiency virus was 
discovered in 1983. For the discovery of the virus Luc Montagnier and 
Francoise Barre-Sinoussi were bestowed with nobel prize in 2008. 
 (1)
 
 
HIV has become a  pandemic  with global statistics showing 35.3 
million people living with HIV in 2012 and World wide around 2.3 
million people have become newly infected with HIV and around 1.6 
million people died from AIDS and its complications . From the 
beginning of the AIDS epidemic an estimated 36 million people have 
died of AIDS.  
In India around 1.16 lakhs new HIV infections were reported in 
2011 and estimated number of people living with HIV is 20.9 lakhs as per 
2011 statistics. Wider access to Antiretroviral therapy has caused a 
decrease in estimated annual deaths due to AIDS by 29% in 2011 as 
compared to 2007 numbers.
(3)
 
 HIV infection affects almost every organ of the body including the 
endocrine system. Adrenal gland is most often involved but clinical 
adrenal dysfunction is not usually seen.  Thyroid disorder is also common 
in HIV infection. Though clinical manifestation is not common thyroid 
hormone level alteration is common in HIV infections and has been 
found in many previous studies.  
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 Thyroid function alteration is present in 10 – 15 % of patients with 
HIV infection. Both hypothyroidism and hyperthyroidism may be seen. 
Most common is subclinical hypothyroidism. In the HAART era around 
10 % patients are noted to have elevated TSH levels. This may be due to 
immune reconstitution 
(5)
 . In advanced HIV disease , infection of thyroid 
gland due to opportunistic pathogen like pneumocystis jeroveci, CMV, 
mycobacteria, toxoplasma or Cryptococcus  may cause thyroid 
dysfunction.Thyroid dysfunction has been in many studies correlated 
with advancement of infection and lowered CD 4 cell count. There are 
not many Indian studies to establish these relations, and so this study is 
undertaken.  The thyroid function abnormalities in patients who are not 
already exposed to antiretroviral therapy brings out the effect of the HIV 
infection alone on thyroid glandular function. To include patients with all 
grades of advanced HIV infection  at different severity and different CD4 
count range we have included newly diagnosed HIV patients in our study, 
as,  if not done so , patients with lower CD4 counts and those who are 
eligible for ART by clinical severity of disease would already have been 
started on ART as per NACO guidelines. To avoid the effect of drugs on 
thyroid profile we selected newly diagnosed HIV patients and there 
thyroid profile was correlated with their clinical stage of HIV disease and 
CD4 counts. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
(1) To study thyroid function abnormalities pattern in newly diagnosed  
HIV patients at varying severity of illness at diagnosis  
(2)  To find out relation between thyroid function abnormalities and 
 severity of   HIV illness – immunological severity as assessed by 
CD4 count and clinical severity as assessed by WHO clinical stage of 
the illness  
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                        REVIEW OF LITERATURE 
 Acquired Immunodeficiency syndrome is a secondary 
immunodeficiency condition which is caused due to infection by Human 
Immunodeficiency virus. In 1981 AIDS was first reported as an emerging 
fatal infectious disease.  HIV is a retrovirus causing profound 
immunosuppression. This immunosuppression makes the infected person 
more susceptible to many unusual infectious organisms leading to 
opportunistic infections. This makes those infected  vulnerable to many 
secondary neoplasms and autoimmune and endocrine and neurologic 
manifestations and thus is a multisystem disorder. It is the sudden 
increased prevalence of rare infections Pneumocystis carinii pneuomonia 
and kaposi’s sarcoma in young homosexual adults and injection drug 
abusers in 1981 that a suspicion towards the emergence of a new 
immunodeficiency disorder with new unrecognized pathogen arose. In 
1983 the causative agent was identified from a patient with lymph node 
enlargement and by 1984 it was established beyond doubt that HIV was 
the etiologic agent responsible for AIDS. Enzyme Linked Immunosorbent 
assay a sensitive test for HIV was then developed by the year next. 
The pattern of  AIDS case reports suggested that this disease agent 
could be  transmitted through sexual contact (homosexual and 
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heterosexual), sharing of drug injecting needles or  Infected blood 
product transfusion, and vertically from mother to child. 
INDIAN SCENARIO  
(1)
   
 First case of  HIV  in India was reported in 1986. It was reported 
first in female sex workers in Chennai, Tamil Nadu.  HIV epidemic in 
India is of Type IV pattern.  In this kind of pattern  new infections occur 
initially in high risk  persons - female sex workers and injection drug 
abusers and after this it spreads to the so called  Bridge Population that is 
the clients of FSW and sexual partners of drug users and then ultimately 
infects the general population. 
        Young adults (15-49 years) account for 89% of the burden of HIV 
infection. The male to female ratio is 3:2 . India has a ‘concentrated 
epidemic’, the prevalence being significantly higher among various high-
risk groups (MSM, IDU, FSW and STD clinic attendees) than among 
antenatal subjects . 
HIV -VIROLOGY 
Human Immunodeficiency virus is a lentivirus, a member of 
retrovirus subfamily.  HIV is cytopathic and cytotoxic and high levels of 
viral gene expression causes death of the infected cell and sometimes 
even the adjascent cells 
(4)
.  
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STRUCTURE OF  HIV  
HIV has an icosahedral structure .It is an enveloped virus .The 
diameter of HIV is  120 nm
(6)
 . It also  has a  lipid bilayer with around 72 
spikes of glycoprotein . The different types of glycoprotein are 
• gp 120  
• gp41 for HIV- 1  
• gp 36 for HIV – 2. 
 
 
 
 
 
 
 
 
Figure 1: HIV Morphology 
  The gp 120 provide binding site for the cellular receptors. The virion has 
2 RNA molecules within the protein capsid 
viral RNA dependent DNA polymerase 
enzyme.The capsid (p24) is surrounded by
enclosed by lipid bilayer.
HIV genome 
The genome of HIV contains 3 structural genes 
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 p24. Within the capsid are 
Pol that is reverse transcriptase 
 a matrix layer (p1
(5)
 
- gag ,pol , env.
Figure 2 .  HIV – 1  genome 
 
7) that is 
(5) 
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In India the most common mode of transmission is heterosexual the 
statistics in India for mode of transmission is shown in the following 
figure 
 
 
 
 
 
 
Figure 3 .  Modes of HIV transmission in India 
The risk of transmission is  
 highest when blood or blood products are the source of infection 
that is more than 90% to 95 %
(12)
 
 15-40% for vertical transmission that is mother to child 
transmission 
 0.5-1% for intravenous and injectable drug users 
 0.2-  0.5 % via   genital mucosal membrane  
9 
 
HIV REPLICATION 
  gp 120 protein binds to the CD4  molecule which is the gp 120 
receptor
(13)
 
 This   requires a co-receptor called  CCR5 which helps the CD4 
molecule for fusion and entry of the HIV 1 .  
  Fusion  of the virion with the host membrane occurs via  gp 41  
  HIV -  RNA  is uncoated and it is  internalized to  the target cell.  
 The enzyme called  reverse transcriptase  of the virion causes the 
reverse transcription of the virion RNA into ds DNA .   
 DNA translocates to nucleus and with the help of integrase , the 
DNA integrates with host chromosome 
 When  cellular activation occurs this leads to transcription of  the 
proviral DNA to mRNA and also to the  virion genomic RNA 
 Then transcribed mRNA is translated to proteins  
 Posttranscriptional modification occurs 
  The  HIV proteins enzyme and also the genomic RNA assemble to 
form the core of the virion.  
 It then acquires plasma membrane of the host cell and buds off 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 .  HIV Replication cycle 
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PATHOGENESIS  
 PRIMARY INFECTION :   
• When there is infection by human immunodeficiency virus 1 
initially in the acute stage there is viral replication in CD 4 + T 
lymphocytes. CD 4 + T cells in the GALT and MALT express HIV 
co-receptor CCR5 and hence are susceptible to HIV-1 infection. 
This infection leads to viral replication which in turn causes high 
HIV RNA titres . It reaches higher to about  Ten lakh  copies per 
millilitre  within a fornight. Due to this high HIV  load  patients 
have  a syndrome known as  Acute Retroviral Syndrome. 
• Following this  fall  in the  peripheral CD4+ T lymphocyte cell 
counts occurs in the primary infection which causes opportunistic  
infections. In few weeks time the CD8 + T lymphocyte begin to 
form in response to HIV and causes control of  multiplication of  
the virus.   
• This leads to decrease in the load  of HIV  which leads to a state 
called as the SET POINT. 
• The rate of progression of HIV  to full blown AIDS is determined 
by the load of the virus at the SET  POINT .  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. HIV Pathogenesis 
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IMMUNITY THAT IS SPECIFIC TO HIV 
• HIV   activates dendritic cell through   TLR  
•  This causes production of  interferon IFN 1  
• This interferon stimulates immunity against HIV 1  
• Interferon 1 also activates CD4+ and CD 8+ cells  
• Natural killer cells - activated when cell is infected with HIV  
• NK cell activation leads to prevention of progression of illness in 
the long run may be by decreasing  HIV multiplication.  
• Humoral immune activation has a latency , it is not reached till 
about maximum load of the virus is reached . this latency is called 
the window period  
• Window period is the period in which there is viremia but the 
antibodies cannot be detected in blood.  
• The antibodies that develop act by preventing the gp 120 from 
reacting with CD4  and other coreceptor. 
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• The depletion of CD 4 is very selective. This is responsible for the 
impaired adaptive immune response in human immunodeficiency 
virus. 
• CD8+T  lymphocytes control the human immunodeficiency virus 
infection by causing  direct cytolysis of the cell which is infected 
by the virus.  
• CD 8 + T cells also secrete  soluble factors called macrophage 
inflammatory protein  one beta which binds to chemokine receptor 
and thus prevents the entry of human immunodeficiency virus into 
the cell. 
• Complete sterilizing immunity which is specific to HIV cannot be 
achieved by the CD8+ lymphocytes,  because of the latent infection 
which remains within the CD4 + cells memory cells that are 
formed soon after the infection. 
• These latent cell are not recognized by the CD 8 +  T cells because 
the quiescent cells are not able to synthesise HIV proteins .  
•  The HIV enzyme reverse transcriptase has got only  low fidelity  
and this leads to mutations with each replication cycle.  
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THE EFFECT OF HIV-1 REPLICATION ON THE 
IMMUNE SYSTEM 
There is immune system activation chronically due to continuous 
viral multiplication. This kind of chronically active immune mechanism 
can cause non - specific inflammatory activation and this leads to 
translocation of the microbes due to decrease in CD4+ T lymphocytes in 
GALT. It is the chronic activation of immune system which leads to the 
fall in the CD 4 + T lymphocytes. 
The  markers of immune system activation on the CD 4+ T 
lymphocytes and the CD 8 + T lymphocytes better correlates with  rate at 
which the CD 4 falls  than does the quanitity of the load of the virus in 
patients who are not treated. There are activation markers detected 
increasingly on the  
 NK cells  
 B cells  
 CD 4 + lymphocytes 
 CD8 + T lymphocytes  
16 
 
This activation of markers is associated with rise in the rate of 
turnover of the cells. NK cells don’t function effectively causing 
ineffective control over other viral infections 
B cell function is also impaired causing hyper- 
gammaglobulinemia and accelerated generation of auto-antibodies. When 
vaccinated the response by production of antibody is impaired when 
CD4+ falls. 
Cells which are most productively infected cells remain alive only 
for shortened time that is approximately 1 day before dying due to the 
cytopathic action of virus and cytolytic T cells of the host or NK cells. 
CD 4 cells which are lost thus lead to CD 4 depletion . The immune 
system which is chronically activated causes the non infected CD 4 + cell 
death and this is the main mechanism of the fall in CD 4 count. The 
qualitative memory response against recall antigen falls earlier that is 
even before CD4 count decreases to less than 200 cells per microlitre. Its 
also found that the CD4 and CD8 cells undergo immune exhaustion and 
hence the immune response mediated by CD 8 cells against the viruses 
like CMV and EBV is qualitatively poor. This is due to anergy and also 
depletion of the CD 4 + T cells which are inevitable for the sustained CD 
8 + lymphocyte response. 
 
17 
 
 
 
 
 
 
 
 
 
 
Figure 6 . Immune Response to HIV Infection 
Autoimmune Phenomena 
 The autoimmune phenomena in HIV-infection is due to chronic 
immune system activation as well as molecular mimicry by viral 
components.  
 Autoimmunity usually occur in the absence of autoimmune disease, a 
number of clinical manifestations due to autoimmunity are described. 
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 Autoimmune phenomena include antibodies to lymphocytes, to 
platelets or to neutrophils. Antiplatelet antibodies thus may cause 
thrombocytopenia of HIV disease. 
 Antibodies to nuclear and cytoplasmic components of cells and  
antibodies to cardiolipin; CD4 molecules; CD43 molecules; C1q-A; 
variable regions of the T cell receptor ; Fas; denatured collagen; and 
IL-2. In addition, autoantibodies to serum proteins, including 
albumin, immunoglobulin, and thyroglobulin, have been reported.  
 There is antigenic cross-reactivity between HIV viral proteins (gp120 
and gp41) and MHC class II determinants, and anti-MHC class II 
antibodies  reported in HIV infection.  
 These antibodies could potentially lead to the elimination of MHC 
class II–bearing cells via antibody-dependent cellular cytotoxicity 
(ADCC), although this has not been clearly demonstrated to occur . 
In addition, regions of homology exist between HIV envelope 
glycoproteins and IL-2 as well as MHC class I molecules.  
• The occurrence and/or exacerbation of psoriasis, idiopathic 
thrombocytopenic purpura, Graves' disease, antiphospholipid 
antibody syndrome, and primary biliary cirrhosis in HIV are thus 
seen. 
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•  With the effective antiretroviral therapy, an immune reconstitution 
inflammatory syndrome (IRIS) has become common. IRIS is an 
autoimmune-like phenomenon characterized by a paradoxical 
deterioration of clinical condition, which is usually 
compartmentalized to a particular organ system, in individuals in 
whome cART has recently been initiated. It is associated with a 
decrease in viral load and at least partial recovery of immune 
competence, causing rise in CD4 count . 
 
 
 
 
 
 
 
 
Figure 7. Course of HIV Infection 
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Clinical Features of AIDS 
It can be of mild disease to severe. They range from a mild acute illness 
to severe disease. Symptoms range from fever with weight loss or 
diarrhea or generalized lymph node enlargement or opportunistic 
infections or neurological diseases and also secondary neoplasm. The 
typical infectious diseases and neoplasms in HIV and AIDS is detailed in 
the clinical stages of infections. Opportunistic infections are the most 
common cause of mortality in AIDS patients. The prevalence of 
infections can be reduced by the treatment with  HAART.  
NACO GUIDELINES  
(7) 
In India the Case Definition  for AIDS   
Case definition for AIDS in India , was revised in October, 1999  by the 
national AIDS control organisation 
Case Definition of  AIDS in  persons > 12 years  
1. Two positive tests for HIV infection by ELISA/ RAPID / SIMPLE  test 
AND 
2. Any one of the following criteria:- 
a)  Significant weight loss (> 10% of body weight) within last one month 
Chronic diarrheoa and prolonged fever  
21 
 
b) Tuberculosis:  may be Extensive pulmonary or disseminated, or  
miliary, or extrapulmonary tuberculosis. 
c)  Neurological impairment is present that is preventing independent  
activities of daily living, not known to be caused by conditions that 
are  unrelated to HIV   
d)  esophageal candidiasis 
e)  Clinically  life -threatening / recurrent episodes of pneumonitis  
f)  Kaposi’s Sarcoma 
g)  Other conditions:- 
 Cryptococcal meninigitis  
 Neurological  Toxoplasmosis 
 Cytomegalovirus retinitis 
 Recurrent H. zoster or  herpes infection involving multiple dermatomes  
Disseminated  molluscum 
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DIAGNOSIS OF HIV  
The diagnosis of HIV infection is by one of the following 
 The demonstration of antibodies  against  HIV  
 The  direct detection of HIV or one of its components. 
(10)
 
Antibodies to HIV generally appear in the circulation 2 to 12 
weeks after infection. The standard screening test for HIV infection is the 
ELISA- Enzyme linked immunosorbent assay. This solid phase assay 
considered as a screening test with a sensitivity of >99.5%.
(6) 
The western blot test is a highly specific test; it detects specific 
antibody to viral core protein (p24) and envelop glycoprotein gp41.
(8) 
Quantitative nucleic acid testing. : 
• Polymerase chain reaction (PCR) 
• the branched  DNA (b-DNA) 
• the  nucleic acid sequence-based amplification (NASBA) 
• ligase chain reaction (LCR) 
• quantitative detection of reverse transcriptase activity.  
"Viral load" testing can be used  as a prognostic and as a 
therapeutic marker.
(9) 
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I. The screening tests  
1) ELISA test for different viral antigens 
2) Rapid tests 
a) Dot blot assay 
b) Particle agglutination 
c) HIV spot and coombs test 
d) Flowmetric microparticulate technologies  
The sensitivity of the ELISA is > 99.5%, the specificity of positive results 
by two different techniques approaches to 100% even in low risk 
population.
(10)
  Factors associated with false positive tests are 
autoantibodies,  hepatic disease, recent influenza vaccination and acute 
viral infection. 
II. The confirmatory tests are: 
1) Western blot 
2) Immunoblot 
3) Line immuno assay 
4) ELISA with different antigen system or with different principle of test 
which makes the test more specific 
5) Indirect fluorescent antibody test (IFA) 
6) Radio immune precipitation test (RIPA ) 
24 
 
7) Polymerase Chain reaction ( PCR) for HIV RNA 
The confirmatory test commonly used is the western blot test. Its 
specificity when combined with ELISA is >99.99%. The indeterminate 
results occur with early HIV infection, HIV-2 infection, autoimmune 
diseases, pregnancy and recent tetanus toxoid injection.
(10)
  But as the test 
is cumbersome and also costly  the practice now is to perform two 
different types of ELISA or an ELISA with any of the rapid tests.  A 
serum positive in both tests is considered positive. This is used in the 
diagnosis of HIV infection by NACO guidelines. 
Revised World Health Organization clinical staging of 
HIV/AIDS for adults and adolescents (2005)  
(75)
 
 World Health Organization developed the clinical staging 
and immunological classification of HIV and related illness to help those 
countries out where inadequate resource makes lab measurements of CD 
4 counts and HIV viral load in plasma not feasible. The WHO clinical 
stage can be used to determine the eligibility of the patient for 
antiretroviral treatment. Medical decision for HIV patients is made 
entirely based on the clinical features. This staging system is a practical 
and also accurate way  to manage HIV patients with many international 
studies showing agreement between the clinical features in staging 
system and CD 4 count. 
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Table 1: WHO CLINICAL STAGES OF  HIV/AIDS 
WHO CLINICAL STAGE DISEASE 
WHO Clinical Stage I Asymptomatic  
Persistent generalized lymphadenopathy 
WHO CLINICAL STAGE DISEASE 
WHO Clinical stage II unexplained weight loss <10% 
Recurrent bacterial URI 
Angular chelitis 
Recurrent oral ulcer 
Seborrheic dermatitis 
Onychomycosis 
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Table 1: WHO CLINICAL STAGE of HIV / AIDS 
 
WHO CLINICAL STAGE III weight loss greater than 10 percent 
not otherwise explained 
 Unexplained chronic diarrhea 
 Persistent fever which is 
unexplained 
 Persistent oral candidiasis 
 Oral hairy leukoplakia 
 Pulmonary TB 
 Severe bacterial infections 
 Nectrotizing stomatitis or gingivitis 
 Anemia which is not explainable 
Hb < 8 or neutrophil count less than 
500 or platelet count less than 
50000 per microlitre 
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WHO CLINICAL STAGE IV Extrapulmonary TB 
 PCP  pneumonia 
 Recurrent severe bacterial pneumonia 
 Central nervous system toxoplasmosis 
 HIV encephalopathy 
 HIV wasting syndrome 
 Cryptococcosis  
 Progressive multifocal 
leukoencephalopathy 
 Esophageal candidiasis 
 CMV infection 
 Lymphoma  
 Kaposi sarcoma 
 HIV Associated Nephropathy 
 HIV associated Cardiomyopathy 
 Invasive carcinoma cervix 
 Visceral leishmaniasis 
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HIV A MULTISYSTEM DISEASE 
Respiratory System 
Infectious pulmonary process
(15)
  : Mycobacteria tuberculosis 
 pneumococcal pneumonia with sepsis 
     Haemophilus influenza pneumonia  
     Pseudomonas aeruginosa 
     Pneumocystis jerovecii pneumonia 
Non infectious pulmonary disease: Kaposi’s sarcoma 
     Non Hodgkin’s lymphoma 
     Interstitial pneumonitis   
Sinusitis :   Bacterial sinusitis 
  Fungal sinusitis 
Pneumocystis jerovecii : most common opportunistic infection in the HIV 
infected patients which has typical radiological features like the Chest X 
ray showing the perihilar or diffuse infiltrates 
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Central Nervous System 
(15) 
• Toxoplasmosis – most common space occupying lesion in patients 
with HIV  
• CNS lymphoma – Non Hodgkin’s lymphoma 
• AIDS dementia complex – most common cause of altered 
sensorium in   HIV patients.  
• Cryptococcal meningitis  
• HIV myelopathy : spastic paraparesis and sensory ataxia 
• Progressive multifocal leukoencephalopaty : viral infection – JC 
virus which destroys myelin by infecting the oligodendrocytes .It 
usually Presents with aphasia, limb apraxia , ataxia, hemiparesis, 
cortical blindness, focal signs related to occipital lobe. 
Peripheral Nervous System Diseases 
• Sensory neuropathy , Mononeuropathy 
• Inflammatory demyelinating polyneuropathy  
• Transverse Myelitis 
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Myopathy 
Proximal muscle myopathy 
Zidovudine can also induce myopathy 
Retinitis 
CMV retinitis –fluffy opacities / exudates 
 perivascular Hemorrheage 
Oral Lesions  
• Oral candidiasis 
• Hairy leukoplakia 
• Angular cheilitis 
• Aphthous ulcers 
• Gingival disease 
Gastro intestinal involvebilaiment 
• Candidial oesophagitis  
• Heptatic involvement  :  HIV causes chronic active hepatitis 
 Hepatitis C virus infections   
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 Hepatitis B virus hepatitis 
 Cytomegalovirus infection of the liver 
 Mycobacterial disease of the liver  
 Lymphoma involving the liver 
• Biliary disease : these diseases are induced by Cytomegalovirus , 
cryptosporidia  and microsporidia 
Acalculous cholecystitis , Sclerosing cholangitis , Papillary stenosis 
• Enterocolitis : 
Bacterial : campylobacter , Salmonella , Shigella 
Virus : Cytomegalovirus , Adenovirus 
Protozoans :   entamoeba,   Giardia  etc 
HIV itself can cause  the enterocolitis known as AIDS enteropathy 
HIV gastropathy and malabsorption – HIV infected patients secrete 
less acid  they become prone to many infections like salmonella and 
campylobacter. 
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Skin Manifestations
(16) 
 Herpes simplex infection is common and often more severe in AIDS 
patients .Herpes zoster is also common in HIV disease 
 Molluscum contagiosum : spread widely over the patients skin  
Staphylococcus: most common bacterial skin disease. Presents as 
folliculitis , superficial abscess, bullous impetigo. It can progress to sepsis 
Bacillary angiomatosis : Bartonella  mimic  lesions of kaposi’s sarcoma 
Fungal infections : dermatophytes and candida  
Seborrhoeic dermatitis caused by Malasezzia furfur 
Xerosis : severe pruritis in HIV patients with no rash  
Psoriasis can be very severe in patients who are HIV seropositive 
HIV Related Malignancies
(15) 
AIDS defining malignancies are  
1.Kaposi’s sarcoma ,  2.Non Hodgkins lymphoma,  3.primary lymphoma 
of the central nervous system and 4. invasive cervical carcinoma 
Endocrine manifestations in HIV infection 
Adrenal Insufficiency: deficiency of the glucocorticoid and or the 
mineralocorticoids secreted by the adrenal gland. In HIV patients at 
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autopsy there is found to be high incidence of adrenal involvement.
(17,19 )
 
CMV infection of adrenal gland is found.
(18)
 But clinically and 
biochemically, adrenal insufficiency is uncommon. The trio of 
hyperkalemia hyponatremia and hypotension in HIV patients is not 
always adrenal insufficiency, it can occur due to many causes in 
advanced HIV disease. Drugs like ketoconazole used to treat fungal 
infection in HIV patients causes inhibition of adrenal corticosteroid 
synthesis
(20)
 and it also causes blunting of the cortisol response when 
ACTH is given
(21)
. Rifampicin alters the metabolism of the 
glucocorticoids causing increased excretion of the steroids making 
increased glucocorticoid replacement to achieve therapeutic levels.
(22) 
HYPOGONADISM 
The clinical features are fatigue, loss of energy, depressed mood 
and loss of libido and poor self esteem
(23)
.  Frank hypogonadism is not 
seen instead borderline low testosterone level is found in HIV patients 
which has functional importance and need be treated with Androgen 
replacement at moderate doses. Hypogonadism should be thought of in 
HIV infected patients with weight loss or infection or symptoms specific 
of hypogonadism like altered growth of hair and beard and sexual 
dysfunction or testicular atrophy
(24)
. Estimation of Total serum level of 
testosterone is to be done. Normal value is around 200 to 250 ng/d to 
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1000 to 1100 ng/dl . Those found to have <450 to 500 ng/dl need to be  
treated. Serum estradiol level is used in women to assess for 
hypogonadism. The therapy is testosterone intramuscular injection every  
one to three weeks so that approximately 100mg/week is provided. 
Oxandrolone an oral androgen is now approved for use in AIDS-
associated weight loss and the dose used is 20 mg.
(27) 
PITUITARY DYSFUNCTION 
There are reports of Toxoplasma gondii infiltrating the pituitary
(28)
 
in advanced stages of HIV disease. Inadequate ACTH response to adrenal 
insufficiency and hypogonadotropic hypogonadism. Elevated levels of 
prolactin is also reported in advanced HIV disease. Posterior pituitary 
dysfunction can present as hyponatremia.
(29)
 Hyponatremia is due to 
stress or drug induced SIADH 
(32)
. Another differential diagnosis is renal 
salt wasting syndrome.
(30)
 Isolated hyponatremia is commonly seen in 
HIV disease in advanced stage of illness and it had a poor prognosis.
(31)
 
PANCREATIC DYSFUNCTION 
 This causes hypoglycemia if hyperinsulinemia occurs and diabetes 
if hypoinsulinemia occurs. Pentamidine 
(33) 
which was used to treat 
pneumocystis pneumonia caused pancreatic endocrine disturbance which 
caused hypoglycemia. Pentamidine is a strong beta cell toxin. Rapid 
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destruction of beta cell causes rapid release of large quantity of insulin 
leading to hypoglycemia.
(34)
 The drug remains in the system for weeks 
due to long half life hence hypoglycemia may be persistent for days to 
weeks. Later on patient can go in for diabetes mellitus with or without 
ketoacidosis.
(35)
 
THYROID GLAND FUNCTION
 
             Abnormal thyroid function pattern called the sick euthyroid 
syndrome is found in advanced HIV disease. Other than this subclinical 
hypothyroidism and hypothyroid patterns are also seen in HIV patients at 
various stages of illness
(38)
. There are some reports of pneumocystosis
(39)
 
of thyroid gland and involvement of thyroid gland by cytomegalovirus
(40)
 
and  also Kaposi sarcoma.
(41) 
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                           THYROID OVERVIEW  
  Normal thyroid gland is made up of two lobes joined by the 
isthmus. It is 0.5 cm thick,  2cm wide, and 2cm in height. It lies anterior 
to  trachea that is  it lies between the cricoid  and the suprasternal notch. 
PHYSIOLOGY OF THYROID HORMONE
(42) 
Iodine absorbed in the gut and is converted to iodide and is 
transferred into the thyroid cell by “iodide trapping”. The trapped iodine 
is oxidised to iodine and combines with tyrosine to form 
monoiodotyrosine (MIT) and Diodotyrosine (DIT). The   MIT   and   DIT  
are coupled to form T3, where as two  DIT couple to form T4. Oxidation, 
Iodination and coupling reactions are catalyzed by the enzyme Thyroid 
Peroxidase. Thyroid hormones are then bound with thyroglobulin till 
secretion. T4 is secreted from the thyroid gland in about twentyfold 
excess over T3. Both  thyroxin and the T3  are  bound to plasma proteins, 
including  thyroxine binding globulin (TBG), 25 trans- thyretin   and also 
albumin. The concentration of TBG is relatively low (1–2 mg/dL), but 
because of its  high  affinity for  the thyroid hormones , it carries about 
80% of the hormones that are bound. Albumin has comparatively low 
affinity for thyroid hormones but has high plasma concentration  (3.5 
g/dl) , that it binds around 10% of  the  T4 and  30% of  T3. TTR carries 
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about 10% of T4 but little T3. In the periphery T4 is converted to T3 by 
the deiodinase enzymes. Type I deiodinase, which is located primarily in 
thyroid, liver, and kidneys, has a relatively low afinity for T4. Type II 
deiodinase that has a higher affinity for T4 and is found primarily in the 
pituitary gland, brain, brown fat, and thyroid gland. Expression of type I 
deiodinase allows it to regulate T3 concentrations , this is  important in 
levothyroxine (T4) replacement.  
 
 
 
 
 
 
 
 
 
 
Figure 8   :  Thyroid hormone synthesis 
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MECHANISM OF ACTION: 
Thyroid hormone enters the cell and the T3 gets bound to thyroid 
receptors located inside the nuclei. TR is of two types TR alpha and TR 
beta.  TR alpha is abundant in brain, kidneys, muscle, gonads and heart 
and the TR beta is present in pituitary and liver. T4 can also get bound  
but the binding is not as avid. The hormone receptor complex is then 
bound to the DNA via the Zinc fingers thus regulate expression of 
different genes that code for enzymes and thus regulates cell function. T3 
binds with receptor 10–15 times greater affinity than T4, which explains 
its increased hormonal potency.  T4 is produced in excess of T3 but 
receptors are occupied mainly by T3. 
Regulation of the Thyroid Axis 
TSH, secreted by anterior pituitary controls the thyroid axis and 
hence is a useful marker of thyroid hormone action. The thyroid axis is a 
feedback loop. Hypothalamic TRH stimulates the pituitary for the 
production of thyroid stimulating hormone, which, then stimulates the 
synthesis and secretion of the thyroid hormone. The thyroid hormones act 
mainly via TR beta  and  is fed back to cause inhibition of TRH and TSH 
secretion. The SET POINT in the axis is thus established by the thyroid 
stimulating hormone and TRH being the most important positive 
regulator of TSH synthesis and secretion. 
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Figure 9 : Hypothalamic – Pituitary – Thyroid Axis 
Like other pituitary hormones, TSH is released in a pulsatile maner 
and exhibits a diurnal rhythm and  the highest level of TSH secretion  
occurs at night. TSH has a relatively long plasma t ½  that is around 50 
minutes.  TSH is measured using immunoradiometric asays that are 
highly sensitve and specific. TSH is used in the diagnosis of  
hyperthyroidism where there is low TSH  and also hypothyroidism where 
there is high TSH. 
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The TSH is extremely sensitive to the levels of thyroid hormones 
in circulation and can be used as a useful tool in detection of thyroid 
abnormalities  rather than using T4 or T3 levels. The thyroid dysfunction 
is classified as hypothyroidism, hyperthyroidism, subclinical 
hyperthyroidism depending upon the TSH and thyroid hormone levels. 
Table 2: Thyroid dysfunction classification 
Thyroid status TSH  Thyroid hormone 
Normal Normal Normal  
Hypothyroidism High  Low  
Hyperthyroidism Low  High  
Subclinical hypothyroidism High  Normal   
Subclinical hyperthyroidism Low  Normal  
HYPOTHYROIDISM 
Hypothyroidism is due to decreased effect of thyroid hormones on 
tissues.  
(42) 
The incidence is approximately 1% to 2%.
(43 )
The serum TSH 
level greater than  10mU/L is associated with decreased thyroid hormone 
status.  
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Hypothyroidism is of two types primary and secondary 
Table 3 : PRIMARY HYPOTHYROIDISM 
Autoimmune  Hashimoto’s  and atrophic thyroiditis 
Iodine deficiency Environmental or nutritional  
Iatrogenic I 131 use, thyroidectomy radiation 
therapy to neck 
Medications  Amiodarone, Lithium, antithyroid drugs 
Congenital  Absent or ectopic thyroid  
Dyshormonogenesis 
TSH receptor mutation 
Infiltrative disorder Amyloidosis, Sarcoidosis scleroderma 
 Hemochromatosis 
Transient  Silent thyroiditis 
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Table 4: SECONDARY HYPERTHYROIDISM 
Hypopituitarism Tumors, Pituitary  surgery 
Irradiation, Sheehans syndrome 
Hypothalamic disease Tumors, Trauma, Infiltrative disorder 
Table 5 :Clinical features of hypothyroidism 
Symptoms  Signs  
Weakness, Tiredness Carpal tunnel syndrome 
Dry skin, hair loss Dry coarse skin, Diffuse alopecia 
Cold intolerance Cold peripheries 
Poor concentration and 
memory, Paraesthesia 
Delayed DTR, Pseudomyotonic 
reflex 
Weight gain and poor appetite Puffy hands and feet  
Constipation  
Dyspnoea Pericardial and pleural effusion 
Hoarseness  
Menorrhagea  
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HYPERTHYROIDISM 
Hyperthyroidism
(45)
 is due to excessive action of thyroid hormones 
in the body tissues. Thyrotoxicosis is a synonym. Grave’s disease is the 
commonest cause of  hyperthyroidism. Approximately 0.5% to 1% of the 
population suffers from hyperthyroidism. The TSH levels are suppressed, 
<0.1mU/L and associated with high levels of thyroid hormones. It is of 2 
types that is primary and secondary, the different causes of each is 
included in the table below. 
Table 6: HYPERTHYROIDISM 
Primary hyperthyroidism Secondary hyperthyroidism 
Graves disease TSH secreting pituitary adenoma 
Toxic MNG Thyroid hormone resistance 
Toxic adenoma Gestational  thyrotoxicosis 
Thyroid malignancy  
Thyrotoxicosis + hyperthyroidism  
Subacute granulomatous thyroiditis  
Silent thyroiditis  
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Table 7 : CLINICAL FEATURES OF HYPERTHYROIDISM  
SYMPTOMS SIGNS 
Hyperactive  Tremors  
Irritable  Goitre 
Dysphoria Warm moist skin 
Palpitation  Tachycardia and atrial fibrillation 
Fatigue  Lid retraction lid lag 
Weight loss and increased appetite Tachycardia 
Diarrhoea Proximal muscle weakness 
Polyuria   
Oligomenorrhoea ,loss of libido Gynaecomastia 
SUBCLINICAL HYPOTHYROIDISM 
According to the latest consensus statement by the American 
asociation of clinical  endocrinologists , the American thyroid association  
and the endocrine society , subclinical hypothyroidism
(46)
 is defined as an 
elevated serum TSH level(4.5mU/L to 10mU/L) asociated with normal 
total or free T4 and T3 levels. Overall the prevalence is 2% to 8%    
general population
(41) 
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SUBCLINICAL HYPERTHYROIDISM 
Subclinical hyperthyroidism is defined as low serum TSH levels 
(0.1mU/L to 0.4mU/L) asociated with normal T4 and T3 levels.
(40)
 
Subclinical hyperthyroidism prevalence is about 2%. Most often 
subclinical disease is asymptomatic but some patients show symptoms of 
deficiency of thyroid hormone in subclinical hypothyroidism.  
SICK EUTHYROID SYNDROME 
Thyroid hormone alteration occurs in many diseases which affect 
mainly the T3 level in the absence of any intrinsic thyroid glandular 
disease. It is also called Low T3 syndrome, Non thyroidal illness 
syndrome or Thyroid hormone adaptation syndrome. Sick euthyroidism 
syndrome occurs in the following conditions 
• Acute critical illness – life threatening infections or Myocardial 
infarction  
• Burns or polytrauma 
• Post operative period  
• Diabetes mellitus  
• Renal diseases 
• Liver disease 
• Malignancy 
• Patients on chronic steroid therapy , phenytoin use  
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Sick euthyroid syndrome is most often associated with fall in total 
and free T3 with normal T4 and TSH.  The magnitude of fall in the T3 
correlates with the severity of the disease. In this condition the peripheral 
conversion of T4 to T3 by deiodinase is abnormally low and instead is 
converted to Reverse T3. This is one mechanism although the main 
mechanism is decreased clearance than production for increased rT3. T4  
by alternate metabolism is converted to inactive T3 sulfate. With increase 
in disease severity there is decrease in serum T4 also called the low T3 
T4 syndrome. Though T level falls the free T4 remains within normal 
limits or slightly on the lower side. T3 T4 even if is lower, serum TSH 
levels are normal or reduced , this is the main difference from primary 
hypothyroidism where TSH level rises with fall in T3 T4 levels. 
LABORATORY EVALUATION 
 Estimation  of Thyroid Hormones 
TSH levels change in response to changes in T3 and T4 , so initial 
determination of  TSH  is to be first done. If TSH is abnormal then 
measurement of T3 T4 to confirm diagnosis of hyperthyroidism or 
hypothyroidism. In hyperthyroidism TSH level is low due to feedback 
inhibition by elevated T3 T4. In hypothyroidism TSH level is high. 
Radioimmunoasay is used for serum total T4 and total T3 estimation. 
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 T4  and  the T3 are greatly bound to proteins and this protein 
binding is affected by many factors like medications pregnancy or genetic 
make up. So it is useful to measure free T3. Moreover in pregnancy there 
is increase in thyroid binding globulin which leads to increase in total 
thyroid hormone levels similarly when there is decrease in thyroid 
binding globulin as in nephrotic syndrome, total thyroid hormone level is 
decreased. 
 Tests to determine Thyroid Dysfunction etiology 
 TPO antibodies: autoimmune thyroid disease is detected  by measuring 
antibodies versus Thyroid peroxidase and thyroglobulin. It is found that 
around 10 % of euthyroid women and 2 % of euthyroid men have thyroid 
antibodies. In autoimmune hypothyroidism TPO antibodies is universally 
found whereas in graves disease upto 80 % have this. 
THYROID STIMULATING ANTIBODIES : These stimulate the TSH-R  
in Graves disease. 
THYROGLOBULIN LEVELS : It is elevated in thyrotoxicosis of all 
kinds except thyrotoxicosis factitia. Thyroglobulin levels are increased in 
thyroiditis. n of thyroid hormone. 
 RADIOIODINE UPTAKE AND THYROID SCANNING: The thyroid 
gland selectively transports radioisotopes of iodine -  (123I, 125I, 131I) 
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Nuclear imaging of Graves disease is found to have increase in size of the 
gland and more tracer uptake  .Thyroid scan has also role in monitoring 
patients with thyroid cancer.  
d) Thyroid Ultrasound  
USG is used  in the diagnosis of nodular thyroid disease. 
MANAGEMENT 
Hypothyroidism:  
• Levothyroxine 
(47)
 is the treatment of choice. Levothyroxin is 
converted to thyroxin in the body. It is partially, the more active 
thyroid hormone. If there is no residual thyroid function, the daily 
replacement dose of levothyroxine is usualy 1. 6 microgram/kg 
body weight (typicaly 10–150 microgram). 
•  Adult patients who are less than sixty years without evidence of 
heart disease may be started on 50-100  microgram  levothyroxine 
(T4) daily.  
• The dose adjustment is based on  TSH levels, with target of normal 
TSH. TSH response is slow and so should be repeated almost 2 
months after starting levothyroxin or change of dose.  
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Hyperthyroidism : 
The hyperthyroidism of Graves' disease is treated by decreasing the 
synthesis of the thyroid hormones using the drugs called antithyroid 
medications and by decreasing the thyroid tissue by radio- iodine ablation  
or by thyroidectomy. Antithyroid drugs are propylthiouracil, carbimazole 
and its  active metabolite  methimazole. All of these block  TPO enzyme ,  
thus reducing oxidation  of and organification of the  iodide molecule.  
• Propylthiouracil
(47)
 blocks  deiodination of T4 to Triiodothyronine  
• The starting dose of carbimazole or methimazole is usually 10–20 
mg every 8 or 12 h, and changed to daily once dosage after 
euthyroidism is attained. 
• Propylthiouracil is given at a dose of 10–20 mg once in  6–8 hours  
• TFT and clinically patient is reviewed  3–4  weeks after initiating 
therapy and then the dose is altered based on the free T4 levels.  
• It takes about six to eight weeks after therapy initiation to achieve 
euthyroidism 
•  TSH levels often remain suppressed for several months and 
therefore do not provide a sensitive index of treatment response.  
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• The usual daily maintenance doses of antithyroid drugs in the 
titration regimen are 2.5–10 mg of carbimazole or methimazole 
and 50–100  mg of propylthiouracil.  
• In the block-replace regimen, the initial dose of antithyroid drug is 
held constant, and the dose of levothyroxine is adjusted to 
maintain normal unbound T4 levels. When TSH suppression is 
alleviated, TSH levels can also be used to monitor the 
effectiveness of treatment 
• Maximum remission rates of up to 30– 50%  are achieved by 
around 2 years for the titration regimen and by 6 months for the 
block-replace regimen. 
• Propranolol (20–40 mg Q6H)  or atenolol, are used  for controlling 
the  adrenergic symptoms  mostly in the early stages of diseases 
before the antithyroid drugs action becomes  effective.  
• Radioiodine acts by destroying thyroid cells and may be  used as a  
initial therapy or for relapse  after a trial with the  antithyroid 
drugs.  
• Subtotal or near-total thyroidectomy is an option for patients who 
relapse after antithyroid drugs  
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THYROID DYSFUNCTION IN HIV DISEASE 
               HIV disease is associated with many endocrine abnormalities. 
Many of these occur in early and many in late stage of the disease. 
Among those with HIV disease around 2 % develop frank  thyroid illness. 
But what is more prevalent is subtle dysfunction in thyroid
(48)
. Thyroid 
profile derangements are common in HIV patients. Thyroid binding 
globulin level is raised in them and there is inverse correlation with CD 4 
count.(49 ) Abnormal TFT may be due to the stress of the disease in 
patients with advanced disease. Subclinical hypothyroidism is common 
among the  adult  HIV infected patients. Abnormal TFT results may be 
caused by the stress of illness in patients especially those with low CD 4 
counts. Thyroid dysfunction has been reported with the use of HAART. 
 PATTERNS OF THYROID DYSFUNCTION 
Hypothyroidism 
Frank hypothyroidism affects approximately 0.3 % of general 
population. Among HIV infected individuals the prevalence is about 0.1 
to 2.6%. The commonest etiology of hypothyroidism is autoimmune .In 
patients with HAART induced IRIS  hashimotos is rare. Levothyroxine 
replacement is done to treat patients with symptomatic hypothyroidism   
with  the aim of maintaining  the  TSH level at around 0.5–2.5 mU/L.  
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 SUBCLINICAL HYPOTHYROIDISM   
The prevalence of subclinical hypothyroidism is 4.3% in the 
general population. Anti TPO antibodies are positive in 50 to 80 % of 
them Subclinical hypothyroidism
(51)
 is prevalent in HIV patients 
particularly the patients  on antiretroviral drugs approximately 3.5 to 
12.2%  . In these patients anti TPO antibodies are not commonly seen. 
This may point to the fact that it may not be due to autoimmunity.  In  
treating  subclinical hypothyroidism,  patients without HIV infection, 
serial TSH estimation once in 1 to 3 months is needed as the levels may 
become normal in a year in almost one third of the patients. But in those 
with HIV infection such normalization is not seen. If there is persistently 
increased thyroid stimulating hormone level patients need to be treated 
with levothyroxine . Now the guidelines say that in  general population 
treatment is to be offered in those with  TSH level more than10 mU/L and 
individual patient wise decision regarding treatment in those who have  
TSH values 4.5–10 mU/L in the sense that those with symptoms of 
thyroid abnormality or who have anti TPO antibody be treated.  Patients 
who are not on levothyroxine, its recommended to do TSH estimation 
every half yearly to yearly to determine progression. 
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Isolated  decreased  FT4 levels  
Decreased Free T4 levels along with normal TSH levels are found 
in HIV patients, with prevalence which is of 1.3%–6.8%.  In adults 
didanosine stavudine and also the drug ritonavir are associated with this 
pattern of   thyroid profile. Decreased free T4 may be due to the 
hypothalamus or the anterior pituitary dysfunction. In one study TSH 
releasing hormone when administered to those with decreased free T4 
had no delayed and no absent TSH release, thus ruling out pituitary or 
hypothalamic dysfunction as a cause of decreased free T4. Those taking 
antiepileptic drugs had low free T4 possibly due to artifact due to the 
intereference of the drug in the estimation of the free T4. The patients 
with low free T4 do not have signs and symptoms of hypothyroidism 
hence the significance of free T4 clinically is not very clear. 
TFT abnormalities due to nonthyroidal illness. 
Low thyroid hormone levels in HIV patients, the possibility of  
Sick Euthyroid Syndrome needs to be considered. It is also called as non 
thyroidal illness. When anyone is suffering from any severe illness of 
which AIDS is one of the kind the deiodinaation of thyroid hormone T4 
is impaired. So there is no enough production of  triiodothyronine and no 
reverse T3 metabolism instead 5’ deiodination of T4 to the inactive 
hormone called reverse T3 occurs which virtually creates  a TFT 
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abnormality pattern. But this TFT abnormality is due to body’s response 
to severe illness rather than due to thyroid glandular function 
abnormality. Since AIDS due to the above described process can produce 
abnormal TFT this should be kept in the mind when interpreting TFT in 
patients with advanced HIV infection. Decreased triiodothyronine and 
elevated RT3 and variable free T4 and a low or normal thyroid 
stimulating hormone level , different patterns based on the grades  of 
severe illness. 
When the patient improves the thyroid stimulating hormone level 
rises and in some it rises above the normal level as both free T4 and 
triiodothyronine come back to baseline and this is similar to subclinical 
hypothyroidism pattern. 
 
 
 
 
 
Figure 10 :    TFT Results in sick euthyroid syndrome 
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Sick euthyroidism was most prevalent approximating  16 %  in 
those with  advanced AIDS before highly active antiretroviral therapy 
became extensively used.   
Treatment of sick euthyroidism requires treatment of the 
underlying severe disease and not hormone replacement. Repeat TFT 
after 1 to one and half months after the severe illness is controlled with 
HAART confirms the diagnosis.  
CONDITIONS CAUSING THYROID FUNCTION 
ABNORMALITIES IN AIDS 
 Opportunistic infection  and malignancies cause thyroid 
dysfunction in AIDS   
 Thyroditis due to Pneumocystis jiroveci and Cryptococcus 
neoformans  
 Bacterial infection leading to suppuration of thyroid gland  
 Infiltration of the gland with lymphoma or kaposi sarcoma .  
Hyperthyroidism  
Symptoms of hyperthyroidism along with increased T3 T4 and 
decreased TSH is classical of hyperthyroidism. The autoimmune 
disorder called as the Graves disease is characterized by the formation of 
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antibodies to TSH receptor is the most common etiology of 
hyperthyroidism in general as well as HIV infected individuals. The IRIS 
which occurs after highly active retroviral therapy initiation is the state at 
which graves usually occurs in HIV infected patients. The IRIS  causing 
exacerbation of Mycobacteria tuberculosis and and other infection 
usually occur in  almost three months of antiretroviral therapy initiation.  
Where  as the graves disease occurs approximately one to three years 
after starting highly active antiretroviral therapy. It is found that CD4 
count increases in two phases after highly active antiretroviral therapy is 
started. One is by CD4 memory cells getting redistributed from the 
lymphoid organs and second phase occurs many months afterwards 
when there is increase in naïve CD 4 lymphocytes.  
BIPHASIC INCREASE IN CD 4 CELLS DURING IRIS 
 
Phase 1 
• CD 4 cells redistributed from lymphoid organs
Phase 2
• Increase in Naive CD 4 cells 
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In patients with TFT patterns of overt hyperthyroidism radioiodine 
uptake study and the scanning of the thyroid gland can discriminate 
between the different etiologies of hyperthyroidism. In Graves there is 
increased  uptake of radioiodine and shows homogenous pattern by scan 
whereas in MNG thyroid or thyroid adenoma shows increased 
radioiodine uptake but heterogenous .  
Decreased radiiodine uptake is found in thyroiditis  both subacute 
granulomatous  and painless thyroiditis. Subacute granulomatous 
thyroiditis  occurs after respiratory tract infection by some viruses causes 
increased thyroid hormone state initially, then around a month or a month 
and a half later causes decreased thyroid hormone status. Painless 
thyroiditis is an autoimmune thyroid inflammation which is quite often 
transient and has anti TPO antibodies. 
Treatment of hyperthyroidism 
Graves' disease can be treated with antithyroid drugs to decrease 
production of thyroid hormone. Radioiodine ablation of the thyroid gland 
or surgical treatment is the definitive treatment for graves disease and 
also for MNG and toxic adenoma.  
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Subacute thyroiditis is treated with NSAID s and if not cured with 
steroids for pain. Beta blockers relieve the adrenergic symptoms. Painless 
thyroiditis only treatment is beta blockers. 
Subclinical hyperthyroidism 
            Subclinical hyperthyroidism predate hyperthyroidism and is 
characterized by decreased TSH, normal free T4 and T3 levels, and no 
symptoms of thyrotoxicosis.  If symptoms are there then antithyroid 
medication or ablation of gland with radioiodine may be required. 
subclinical hyperthyroidism can lead to the following complications – 
atrial fibrillation and decreased mineral density of the bone . So it is told 
to treat those patients with the TSH level less than  0.1 mU/L  or are 
elderly that is more than 60 years or those with osteopenia. Treatment is 
not needed as per guidelines in those with milder disease that is thyroid 
stimulating hormone level of 0.1 to 0.45 mU/L and guidelines ask for 
repeated TFT half yearly or yearly.   
HAART and thyroid dysfunction  
(76)
 
 HAART, particularly stavudine, is associated with a high 
prevalence of subclinical hypothyroidism. Hypotheses are made 
regarding responsible mechanisms and risk factors. Thyroid function 
should be tested and sequentially rechecked in HAART patients. 
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ROLE OF SCREENING THYROID FUNCTION TEST IN 
THYROID DISEASE 
 Older patients may be screened for thyroid dysfunction as there is 
increased incidence of subclinical hypothyroidism  
 TSH level measurement in those with symptoms of thyroid  
function abnormalities or decreased bone mineral density or altered 
lipid profile or depression or atrial fibrillation.  
 If TSH is found to be elevated FT4 is to be estimated  
 If TSH is low  , Both free T4 and T3 need to estimated to rule out 
T3 toxicosis   
 Sick euthyroidism is to be considered in the interpretation of 
altered thyroid function test especially in advanced HIV disease 
Correlation with the type of thyroid dysfunction observed: 
Belttrans et al
(52)
 studied 350 HIV+ patients showing that  
 16% suffered from hypothyroidism  
 Subclinical hypothyroidism  6.6 % 
 hypothyroidism was predominating among the advanced HIV disease 
and the subclinical hypothyroidism was dominant in  other stages of the 
HIV. 
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Jain G et al  a prevalence study which included fifty  HIV  patients at 
different stages of illness. Patients were divided  into two groups
(53)
 
 Group-1 had 25 patients those who had AIDS  
  Group-2 had  25 patients who were HIV+ but who were not 
having AIDS  
  18% had free T 3 levels below the normal range 
 20% patients had decreased FT-4 levels  
  24% patients had  TSH levels above the normal range.  
  20% of those who  had hypothyroidism were found to be among 
the AIDS patients  
  subclinical hypothyroidism predominated among the HIV infected  
who did not have AIDS 
Sunder S et al studied 150 HIV patients. 
(59) 
They divided the study group into 3 
 These patients were divided in three 
 Group A  CD4 < 200 /microlitre 
 Group B  CD 4 200 – 350 / microlitre 
 Group C  CD 4 >350 / microlitre 
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 In group A,   fifteen of them  had subclinical hypothyroidism  and 
eleven had overt hypothyroidism. 
 In group B, 18 had subclinical hypothyroidism and  4 had overt 
hypothyroidism.  
 In group C, 12 patients had subclinical and 1 had clinical 
hypothyroidism 
 hypothyroid as well as subclinical hypothyroid states were seen in 
advanced HIV, and in non-AIDS groups, subclinical hypothyroid state 
was dominant 
(55,56) 
Palanisamy et al
(57) 
Studied alteration in thyroid function in AIDS patients in relation 
to infection with HIV and healthy subjects.  
 No statistically significant difference in the thyroxin concentrations 
in  those with AIDS  was found in comparison to those with HIV 
infection and those who are healthy subjects. 
  FT4 concentration was statistically significantly decreased in HIV  
and  those with AIDS  
  Total triiodothyronine  concentrations were  normal in those 
infected with HIV and  slightly decreased in those with AIDS  
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 T3 level was decreased in AIDS patients.  
 The level of FT3 was  slightly but significantly raised  in HIV 
infected and significantly decreased in those with AIDS 
 The study concluded that thyroid dysfunction is frequent in HIV 
infection and with progression of disease there is a primary 
hypothyroid like stage that occurs in patients with HIV infection. 
Relationship with ART
(59,60,61) 
Beltran et al study 350 HIV patients for thyroid dysfunction. 32% had 
thyroid dysfunction. In a substudy ,age and sex matched groups of 
patients naïve of ART and those on ART were studied for changes. They 
found no difference between the 2 groups which were statistically 
significant. 
 Bongiovanni et al 
(58)
observed statistically significant changes, in the 
form of increased cases of subclinical hypothyroidism(15%) in the 
patients receiving HAART. 
Calaza L et al 
(62)
 Eighty-four patients were evaluated for the study, 
including 49 subjects treated with HAART and 35 naive to antiretroviral 
agents. Subclinical hypothyroidism (defined as an increase of TSH levels 
associated with normal T3 and T4 levels), was detected in 6 patients out 
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of 49 subjects on HAART (12.2%), while no case of dysthyroidism was 
observed in the group of antiretroviral-naive patients (p<0.05). A long 
prior exposure to HAART was reported in all patients (ranging from 27 to 
58 months), and ongoing antiretroviral therapy included stavudine in all 
the 6 cases, lamivudine in four, didanosine in two, saquinavir in three, 
indinavir, nelfinavir and lopinavir/ritonavir in one case each; duration of 
HAART ranged from 21 to 41 months. 
Relationship with CD4 counts
(63,64) 
Most study series have found an inverse correlation of  the CD4 counts 
with TSH values. There were no conclusions drawn in relation to their 
clinical manifestations in the different stages according to CD4 count. 
Sunder et al, studied patients in 3 groups(CD4<200cells/mm3,200- 
350cells/mm3 and >350cells/mm3). Each group had 50 subjects. 
Percentage of low TSH was maximum amongst subjects with CD4 
<200cells/mm3(52%) and least amongst those with CD4 > 350 cells/mm3 
(26%). All the studies owe this inverse correlation to the immune 
reconstitution occurring with advanced disease or the institution of ART. 
Beltran et al, had 2 groups, A:CD4 >200 cells/mm3 and 
B:CD4<200cells/mm3,it found 67.8% hypothyroid in group A and 32.2% 
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in group B. Low CD4 cell count was a risk factor for hypothyroidism in 
the present study.  
(38)
 
Madge S et al 
(65,66) 
It was a retrospective analysis of thyroid function test in HIV patients. 
The prevalence of and factors which are associated with both the clinical 
and the subclinical thyroid dysfunction were studied. Those patients who 
had normal thyroid function tests but had thyroid disease in the past were 
found from the medical records department and was made part of the 
overt category.  
 73% of the clinic population had at least one thyroid function test 
done since 2001. 
 1233 (79%) were male 
 1043 (66%) were white  
 365 (23%) were black African 
 969 (62%) - the main risk factor for HIV was homosexual mode of 
transmission 
 Median age of the study was 37 years.  
 Nine hundred patients (58%) - on highly active antiretroviral 
therapy when the study began.   
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Table 8 :  Madge S  et al results 
 Thyroid dysfunction  Percentage  affected 
 Overt hypothyroidism  2.5 % 
 Overt hyperthyroidism  Less than 1 % 
 Subclinical hypothyroidism  4 % 
 Subclinical hyperthyroidism  <1% 
 Sick euthyroidism  17% 
 Euthyroidism  75.5 % 

 By Multivariate analysis : no independent variable had statistical 
association with overt hypothyroidism  . 
( 68,69) 
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MATERIALS AND METHODS 
Research Design:  
The present study is an observational and prospective study. 
Source of data: 
Patients admitted to and those attending Coimbatore medical 
college hospital as out patients who are newly diagnosed as HIV positive 
as per NACO March 2007 criteria. 
Methodology 
Sample size – fifty  
Sampling method – simple random sampling 
 Fifty patients who were diagnosed to have HIV infection 
according to National AIDS Control Organisation (NACO) March 2007, 
who fulfilled the  inclusion and exclusion criteria who got admitted to 
coimbatore medical college hospital or attended Out patient department 
from september 2013 to february 2014 and  who gave consent to be part 
of the study were included in the study. Data was collected by using pre-
tested proforma meeting the objectives of the study. All enrolled patients 
were investigated for thyroid dysfunction by measuring total T3, total T4, 
TSH  adetailed history and clinical examination. Thyroid function 
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abnormalities were compared with HIV status, CD4 count and WHO 
clinical stage of HIV disease. Patient confidentiality was maintained.  
INCLUSION CRITERIA:  
Newly diagnosed HIV seropositive patients by ELISA testing by NACO 
March 2007 guidelines in the age group 20 to 60 years  
EXCLUSION CRITERIA 
1. Patients already known thyroid disease 
2. Patients already on Thyroxin treatment. 
3. Patient who had undergone thyroid surgery in the past 
4. patients on drugs altering thyroid function – like  
Amiodarone , Lithium, Phenobarbitone, Carbamazepine, Phenytoin ,   
Para amino salicylic acid, Antiretroviral drugs especially stavudine.  
5. Pregnant patients. 
6. patients on oral contraceptive pills 
Investigations done: 
 HIV serology by ELISA 
 CD4 count by Flow cytometry 
 Thyroid function test T3 T4 TSH  by electrochemiluminescence  
method 
 Complete haemogram with ESR 
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 Renal function test 
 Liver function test 
   Chest X ray 
Statistical analysis: 
Statistical methods applied
(67,68,69,70) 
The data that was collected was subjected to descriptive statistical 
analysis. Results on continuous measurement were expressed as Mean 
and standard deviation and results on categorical measurements are 
presented in numbers and percentage. Chi square test was used to assess 
the significance of the results. Odds ratio was used when applicable. The 
results were considered significant if   p value was below 0.05. 
SOFTWARE used :  
•  Microsoft word 2007 and Microsoft excel is used to generate 
graphs and tables. 
• The statistical software, SPSS 19.0  Med Calc 9.01  was used to 
analyse the data. 
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RESULTS 
Table  9  :   Age Distribution of the study group 
 
 
 
 
 
 
 
                            
 
 
 
 
 
Age in years 
Figure 11  :  Age distribution of patients in the study group 
Age in years No: of patients Percentage 
20-30 8 16 
31-40 24 48 
41-50 11 22 
51-60 7 14 
Total 50 100 
 Table 10. : Sex wise distribution of Patients in study group
Sex 
Male 
Female 
Total 
 
Figure   12. : 
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Table  11 : Mean of TFT and CD4 & Standard Deviation of the study group
Table 12     
 
Euthyroid  
Thyroid dysfunction
Total  
 
 
 
 
 
Figure 
 
Mean 
Standard 
Deviation 
71 
euthyroidism 
thyroid dysfunction
:  Thyroid status of the study group gross
Frequency Percentage
31 
 19 
50 100
 
13.  Thyroid status of the study group gross
T3 T4 TSH 
102.85 7.235 5.869 
37.906 1.7343 6.2372 
 
 
 
62 
38 
 
 
CD4 
234.22 
101.316 
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STUDY GROUP
Table 13 :  Distribution of thyroid function in the study group 
Thyroid status Number of patients Percentage 
Euthyroidism 31 62 
Subclinical hypothyroidism 10 20 
Hypothyroidism  6 12 
Hyperthyroidism  1 2 
Low T3 2 4 
Total  50 100 
 
 
 
 
 
 
 
 
Figure 14 : Distribution of thyroid function in study group 
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Table  14  :   Distribution of CD4 count of patients in study group
 
CD4  count
<200 
201-500 
>500 
Total  
 
 
 
 
 
 
 
Figure 15:  Distribution of CD4 count of patients in study group
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Table 15 : Distribution of HIV patients based on  WHO Clinical 
WHO Clinical stage
1 
2 
3 
4 
Total 
 
 
 
 
Figure 16 : Distribution of HIV patients based on  WHO Clinical 
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Table 16 : Haemoglobin levels in HIV patients 
Haemoglobin level Number of patients Percentage 
<6 1 2 
6.1 – 9 13 26 
9.1 – 12 23 46 
>12.1 13 26 
Total 50 100 
 
 
Figure   17  : Hemoglobin levels in HIV patients 
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Table 17 : Distribution of pallor in HIV  patients 
 
Pallor Number of patients Percentage 
Present  24 48 
Absent  26 52 
Total  50 100 
 
 
 
 
 
 
 
Figure 18: Distribution of pallor in HIV patients 
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Table 18: Distribution of oral candidiasis in HIV patients 
 
Oral candidiasis No : of patients Percentage 
Present 30 60 
Absent 20 40 
Total  50 100 
 
 
Figure 19: Distribution of oral candidiasis in HIV patients 
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Table 19:    Association of Age With Thyroid Dysfunction 
Age Euthyroidism Thyroid dysfunction 
21-30 8 0 
31-40 15 9 
41-50 4 7 
51-60 4 3 
Total 31 19 
 
 
 
 
 
 
 
Figure  20 :   Association of Age with Thyroid dysfunction 
Pearson chi square test value : 8.044 
P value 0.045 
Significant  
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Table 20 : Association of Sex with Thyroid dysfunction in HIV 
patients 
Sex Euthyroidism Thyroid dysfunction Total 
Male  9 6 15 
Female  22 13 35 
Total  31 19 50 
 
 
 
 
 
 
 
Figure 21: Association of Sex with Thyroid dysfunction in HIV 
patients 
Pearson chi square value 2.391 
P value 0.122 
Not significant 
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Table 21  : Association 
CD4 Count Number of Euthyroid
<200 
200-500 
>500 
Total  
 
 
 
 
 
 
 
Figure 22  : ASSOCIATION OF CD4  COUNT WITH THYROID 
Pearson chi square  value 5.148
ODDS RATIO-.253 ( CI
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of CD4  Count with Thyroid Dysfunction
 Number of thyroid 
dysfunction 
8 11 
23 8 
0 0 
31 19 
DYSFUNCTION 
   P value .02     Significant
-.075-.853)          Significant 
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Table 22  :  ASSOCIATION OF WHO CLINICAL 
WHO clinical stage Euthyroid patients
1 
2 
3 
4 
Total 
 
 
 
 
 
 
Figure  23 :  ASSOCIATION OF WHO CLINICAL STAGE AND THYROID 
Pearson chi – square value 10.025
P value 0.018,      Significant 
81 
2 3 4
euthyroid
thyroid dysfunction
STAGE AND THYROID 
DYSFUNCTION 
 Thyroid dysfunction 
patients 
4 0 
14 3 
8 7 
5 9 
31 19 
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Table  23:    Association of pallor with thyroid dysfunction 
Pallor Euthyroid Thyroid 
dysfunction 
Total 
Present 11 13 24 
Absent  20 6 26 
Total  31 19 50 
 
 
 
 
 
 
 
Figure24:   Association of pallor with thyroid dysfunction 
Pearson chi square value      5.120  P value  0.024   Significant  
Odds ratio : 0.254  with 95 % CI –   0.075  to  0.856 is statistically  
significant . 
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Table 24 : Association of oral candidiasis with thyroid dysfunction 
Oral candidiasis Euthyroidism Thyroid 
dysfunction 
Total 
Present 16 
53.3 % 
14 
46.7 % 
30 
100 % 
Absent  15 
75 % 
5 
25 % 
20 
100 % 
Total  31 
62% 
19 
38 % 
50 
100% 
 
 
 
 
 
 
 
Figure 25  :  Association of oral candidiasis with thyroid dysfunction 
Pearson chi square value : 2.391   P value : 0.122  Not significant 
 Odds ratio:  0.381 with  CI 0.110   to 1.317  - Not significant 
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Table 25: Association between  Haemoglobin and thyroid 
Haemoglobin in g/dl
<6 
6.1-9 
9.1-12 
12.1 and above 
Total  
 
 
 
 
 
 
Figure 26 : Association between haemoglobin and thyroid 
Pearson chi square value 14.199 
P value 0.003   Significant
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 Percentage 
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13 
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13 
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DISCUSSION 
The study was conducted in the department of General Medicine, 
Coimbatore medical college hospital, Coimbatore. Fifty HIV positive 
symptomatic patients who gave consent to be part of the study were 
enrolled in the study. All patients were evaluated both clinically and 
investigation wise as per the pretested proforma. 
ASSOCIATION OF AGE OF HIV PATIENTS WITH THYROID 
DYSFUNCTION 
In this study the Mean age was    38.84 ±  16.68  SD  . Out of 50 
patients in our study 48% were in the age group of 31 to 40 years and 
22% were of 41 to 50 years age group and 16 % were of 20 to 30 years 
and 51 to 60 years age group people constituted 14% .  Most of the 
studies that were refered showed similar age wise distribution.  
• The Indian study by Palanisamy et al had a mean age of 49 years.  
• The Beltran et al had mean age of 44 years. 
• Study by Sundar et al  had mean age of 35.81 years 
• Madge et al study had mean age of 37 years 
• The study by Carter M et al found that hypothyroidism in HIV 
patients was more in older patients  
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In our study thyroid dysfunction was most prevalent in 31 to 40 
years of age. There was statistically significant association established 
between Age and Thyroid dysfunction with Pearson chi square test  
value : 8.044  P value 0.045, Statistically Significant. 
Sex-wise distribution of HIV positive patients :- 
In our study of the 50 patients studied 20 were males and 30 were 
females that is 40% were males and 60 % were females.   
• In the Beltran et al cohort of 350 subjects,236 were men and 113 
were females.
(38)
 
• Calza et al studied 202 HIV-infected patients of which 95% were 
men.
(7)
 
• Madge et al studied 1565 HIV positive individuals, of  which 1233 
were males and 332 were females.56  That is 79 % male and 21 % 
Most of these studies have a male predominance in their study 
groups.  
• Bongiovanni et al studied 190 consecutive HIV positive subjects 
among which 123 were males and 67 females.
(8)
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• Ketsamathi et al A cross-sectional study was conducted. A total of 
200 HIV-infected outpatients were included. 97 patients (48.5%) 
were male and 103 (51.5%) were female.
(63)
 
Most of these studies had male preponderance in excess.  
Table 26  : Comparison of percentage distribution of males and 
females in different studies 
 
 Palaniswamy 
pashupathi et 
al. 
(72) 
Madge S et 
al
(64) 
Wilfredo 
Richard Engel 
et al. 
Present study 
Male  100% 79% 76% 40% 
Female Nil 21% 24% 60% 
 
Sex-wise distribution of thyroid dysfunction in HIV positive 
In our study of the 50 patients studied, 19 patients had thyroid 
dysfunction. Of these 5 were males and 14 were females that is 26.32% 
were males and 73.68 % were females. Thyroid dysfunction was more 
common in females than male patients.  Statistically gender was not 
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statistically associated with thyroid dysfunction in HIV patients as           
p value is .122.  Thus gender is not associated with thyroid function 
abnormalities in HIV patients. 
Table 27  : Comparison of thyroid dysfunction in male and female 
HIV patients 
Thyroid dysfunction Meena LP et al Present study 
Male  40.66% 26.32.1% 
Female  Nil 73.68% 
 
Category wise distribution of thyroid dysfunction in the 50 
HIVindividuals studied: 
Among the 50 HIV patients studied, 19 had thyroid dysfunction 
that is 38 % and 31 were euthyroid. Of these 20 % had subclinical 
hypothyroidism , 12 % had hypothyroidism ,  2 % had hyperthyroidism 
and 4 % had Low T3 – sick euthyroidism.  
In 2003 Carter M et al The study between May & December 2001, 
included a cohort of 350 patients 16% of patients (n=56) had 
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hypothyroidism, of whom 2.6% had overt hypothyroidism, 6.6% 
subclinical hypothyroidism, and 6.8% a low FT4 level.70 
In 2003 Beltran et al A cohort of 350 patients with HIV was screened. 
Overt hypothyroidism, was detected in 2.6 percent of patients.
(38)
 
Subclinical hypothyroidism was detected in an additional 6.6 percent of 
patients. Low free T4 was found in another 6.8 percent. 
In 2006 Ketsamathi et al A cross-sectional study on 200 HIV-infected 
outpatients was conducted .27 patients (13.5%) had  thyroid function 
decreased. subclinical hypothyroidism 12  whereas five patients had 
increased thyroid function -subclinical  hyperthyroidism .
(59) 
 Table  28  : Comparison of thyroid dysfunction in HIV patients in 
different studies 
 Christopher 
et al 
(74) 
Collazos  
et al
(73) 
Meena LP 
et al 
(54) 
Present 
study 
Euthyroid 63% 74.5% 59.34% 62% 
Thyroid 
dysfunction 
37% 25.5% 40.66% 38% 
90 
 
In our study thyroid dysfunction – 38 % is comparable with the 
studies by Christopher et al  - 37 % . Meena LP et al – 40.66 % . Few 
previous studies reported lesser number of thyroid dysfunction in HIV 
patients.  
Table  29  : comparison of different types of thyroid function 
abnormalitites in HIV patients in different studies 
 Christopher 
et al 
Meena LP 
et al 
Collazos et 
al 
Present 
study 
Euthyroid 63% 59.34% 74.5% 62% 
Hyperthyroid Nil nil 1% 2% 
Hypothyroid 2% 10.66% 2.5% 12% 
Subclinical 
hypothyroid 
35% 30% 1% 20% 
Low T3 Nil nil 17% 4% 
 
In our study hypothyroidism prevalence was 12 % which is 
comparable to that of Meena et al study was 10.66 %. Euthyroidism was 
present in 62 %  which is comparable to Christopher et al 63%. Even if 
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the previous studies show different percentage by thyroid dysfunction , 
total thyroid dysfunction 38% was comparable. And in many studies 
which includes our study also the combined hypothyroidism and 
subclinical hypothyroidism is found to be the commonest. 
Relationship of absolute CD4 counts with respect to HIV patients 
with and without thyroid dysfunction: 
In our study of 50 HIV individuals, the Mean CD4 count was 
234.22 ±101.316.  Among these CD 4 count <200 was found in 19 
patients that is  38 % of them and  201 – 500 in 62 %, that is 31 patients. 
The Mean CD4 ± SD with thyroid  dysfunction was found to be 226.16 
±155.9, and 212.06 ±164.32 without thyroid dysfunction. On fischer’s 
exact test the P value was calculated(0.002) and seen that there is a 
strong relationship between Absolute CD4 count & thyroid 
dysfunction. Thus there is a very strong correlation between a 
dropping CD4 count and occurrence of thyroid dysfunction. 
In 2003 Beltran et al reported subclinical hypothyroidism in 6.6%  and 
subclincal hypothyroidism was3.5%  was correlated with low  CD4 
counts in a Spanish population.(38) 
In 2006 Madeddu G, et al.  Nine out of 23 HIV patients had subclinical 
hypothyroidism TSH was negatively associated with CD4 (P< 0·001). 
(74) 
92 
 
In 2009 Jain et al reported that abnormal thyroid hormone levels which 
correlated with the CD4 counts and the severity of the disease. 
In June 2011 Sundar S et al. studied 150 male HIV positive subjects. 
Out of 50 subjects with CD4 count less than 200/ cu.mm, fifteen   patients 
had subclinical hypothyroidism while 11 patients had overt 
hypothyroidism. Thus CD4 count has strong inverse correlation with TSH 
(r=-0.257, p= 0.002).
(52)
 
ASSOCIATION OF  CD4  COUNT  CATEGORIES AND 
THYROID DYSFUNCTION 
                     Among the 50 pateints in the study, 
 Category A- CD4  count < 200/microlitrewas found in 38 % and  
 Category B- CD 4 count  200-500 /microlitre  was 62 %. 
 Category A – 57.89 % had thyroid dysfunction 
 Category B -25% had thyroid dysfunction  
Thus with category A  the occurrence of thyroid dysfunction is more. 
That is those with CD4 count lesser than 200 had more thyroid 
dysfunction  
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ASSOCIATION OF WHO CLINICAL STAGE WITH THYROID 
DYSFUNCTION 
Out of the 50 patients  
 8 % belonged to WHO clinical stage 1  
  34 % belonged to WHO clinical stage 2 
  30 % to WHO clinical stage 3  
 28 % to WHO stage 4. 
  All of the stage 1 patients were euthyroid.  
 17.65 % of stage 2 patients had thyroid dysfunction 
 46.67% of stage 3 patients had thyroid dysfunction 
 64.3 % of stage 4 patients had thyroid dysfunction 
Thus our study shows that patients with advanced clinical stages 
are more prone for thyroid dysfunction. That is opportunistic infections in 
advanced stages of HIV may be implicated in the pathogenesis of thyroid 
dysfunction. When this was subjected to chi square test statistical 
significant association between WHO clinical stage of HIV disease and 
thyroid dysfunction was obtained. 
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ASSOCIATION BETWEEN HAEMOGLOBIN LEVELS /PALLOR 
AND HIV PATIENTS WITH OR WITHOUT THYROID 
DYSFUNCTION 
In our study of 50 HIV patients, Mean Hb in HIV positive patients 
was found to be 10.706 ± 1.99(g/dl). Mean Hb in patients with thyroid 
dysfunction was 9.87±2.22(g/dl). Mean Hb in patients without thyroid 
dysfunction was found to be 10.06±2.08(g/dl). And the correlation had P 
value of 0.02, which was statistically significant.  
Association of pallor in HIV patients with thyroid dysfunction 
when correlated had a Pearson chi square value      5.120 and P value 
 0.024 which is statistically Significant .The odds ratio for the 
association was found to be 0.254  with 95 % CI –   0.075  to  0.856 
In 2008 Mathews SE et al Study on 187 patients and out of them anemia 
was found in 35.64% of patients in Group A that is on HAART and  
45.34% in Group B  that  without HAART. The prevalence of anemia 
was significantly more in immunological and clinical AIDS that is 
42.05% and 70.58% respectively in contrast to only 28.57% in 
asymptomatic HIV infection.
(71) 
 Thus our study shows significant relation between low 
Hemoglobin and pallor and advanced HIV disease 
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ASSOCIATION OF ORAL CANDIDIASIS AND THYROID 
DYSFUNCTION 
Table 30 : Oral candidiasis and thyroid dysfunction 
Oral candidiasis Euthyroidism Thyroid 
dysfunction 
Total 
Present 16 
53.3 % 
14 
46.7 % 
30 
100 % 
Absent  15 
75 % 
5 
25 % 
20 
100 % 
Total  31 
62% 
19 
38 % 
50 
100% 
60% of  the study population had oral candidiasis and 46.7% of those 
with oral candidiasis had thyroid dysfunction.  Of the 19 patients who had 
thyroid dysfunction 14 had oral candidiasis. Pearson chi square  value for 
the association was : 2.391  and   P value was 0.122 which is not 
statistically significant. Thus oral candidiasis is not associated with 
thyroid dysfunction in HIV but may be due to HIV infection per se. 
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RESULTS COMPILED 
• Among the 50 patients studied, mean age was 38.84±8.34 years.  
• 20 were males and 30 were females.  
•  38 % had abnormal thyroid function test.  
• Of those with thyroid dysfunction 40%-males and 60% - females.  
• Thyroid dysfunction  was more common in female HIV patients. 
• No statistical significant relation was present between thyroid 
dysfunction and gender.  
•  62 % were euthyroid and 38 % had thyroid dysfunction of them 20% 
had subclinical hypothyroidism, 12 % had hypothyroidism, 2% had 
hyperthyroidism and 4% had sick euthyroidism. Thus subclinical 
hypothyroidism was the most common thyroid dysfunction in ART 
naive HIV patients  
• 57.89 % of those with thyroid dysfunction had CD4 count <200 / µL 
p value 0.023. 
•  46.67 % of those with thyroid dysfunction were of WHO clinical 
stage 3 and 64.3 % of stage 4 patients had thyroid dysfunction. 
Pearson chi – square value 10.025  with p value 0.018 which is 
significant statistically 
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• 57.89 % of those with thyroid dysfunction had hemoglobin less than 
9 g/dl   chi square value – 14.199 and p value- 0.003 statistically 
significant.  
• Oral candidiasis is not associated with thyroid dysfunction with HIV 
disease. 
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CONCLUSION 
 In our study thyroid dysfunction was most prevalent in 31 to 40 
years of age. There is statistically significant association between 
age and thyroid dysfunction in HIV patients. 
 Thyroid dysfunction is more common in female HIV  patients in 
our study but statistically the association of gender with thyroid 
dysfunction in HIV patients is absent. 
 Subclinical hypothyroidism is the most common thyroid 
dysfunction in HIV patients, with hypothyroidism the next 
common  and  low T3- sick euthyroidism the next common . 
 Thyroid dysfunction is more common with lower values of CD4 
counts . 
 Thyroid dysfunction is most common in stage 4 WHO clinical 
stage of HIV disease and next common in stage 3, thus thyroid 
dysfunction is more common in advanced HIV disease. 
 Hence thyroid function test screening may be done as screening in 
patients with advanced HIV disease – WHO clinical stage 3 or 4 
and low CD4 counts <200 per microlitre. 
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 Pallor and Haemoglobin<9 g/dl is associated with thyroid 
dysfunction in HIV patients. Hence HIV disease patients with 
anaemia may be screened for thyroid dysfunction. 
 Thyroid function abnormalities need to be detected earlier even at 
subclinical level especially before starting ART  in patients with 
advanced HIV disease as ART initiation itself can push the patient 
with subclinical hypothyroidism to frank hypothyroidism and those 
with hypothyroidism to severe hypothyroidism leading to increased 
morbidity. 
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SUMMARY 
Our study is a prospective study of 50 HIV seropositive patients 
who attended out- patient clinic or was admitted to general medicine 
wards of  Coimbatore medical college hospital , Coimbatore. 
• Thyroid function alteration is common in HIV infection and can be 
detected in early phase of the disease. The thyroid function 
abnormalities are HIV specific and prevalence is higher than that 
of the normal general population. 
• With advanced thyroid disease the prevalence of thyroid disease is 
also higher. 
• This study is done to find the thyroid dysfunction in HIV positive 
newly diagnosed patients who are not started on antiretroviral 
therapy. 
• 50 newly diagnosed HIV positive patients who gave consent for 
the participation in the study were studied, their T3 T4 TSH  results 
were done and it was correlated with their CD4 counts and clinical 
stage of disease. 
• The patients were all evaluated based on the pretested proforma 
and confidentiality of the information was strictly maintained. 
101 
 
• Patients who are known thyroid disease or already on Thyroxin 
treatment and patients on drugs altering thyroid function and  
Patients who had thyroid surgery in the past and  pregnant patients 
and  patients on oral contraceptive pills were excluded from the 
study. 
• Statistical analysis of the data so collected was done. 
• HIV serology was done by ELISA, CD4 counts by flow cytometry 
and T3 T4 TSH by electrochemiluminescence method. 
• The mean age of the study group was    38.84 ± 8.34 SD . 
• There was statistically significant association between age and 
thyroid dysfunction. 
• Our study had 40 % males and 60 % females. 
• There was no significant association between gender and thyroid 
dysfunction in HIV patients. 
• Of the 50 patients studied, 38 % had thyroid dysfunction. 
• Subclinical hypothyroidism was the most common thyroid 
dysfunction In HIV patients in our study. 
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• 57.89 % of those with thyroid dysfunction had CD4 count         
<200 / µL p value 0.023. 46.67 % of those with thyroid 
dysfunction were of WHO clinical stage 3 and 64.3 % of stage 4 
patients  had thyroid dysfunction. 
Pearson chi – square value 10.025 with P value 0.018 which is 
significant statistically. 
• There was statistically relation between CD 4 count and thyroid 
dysfunction. 
• It was found in the study that advanced WHO clinical stage of the  
disease was associated with more occurrence of thyroid 
dysfunction. 46.67 % of  WHO clinical stage 3 and 64.3 % of   
stage 4 patients  had thyroid dysfunction and                                 
chi square value 10.025,    p value 0.018. 
• Thus in our study thyroid dysfunction was much prevalent in those 
with advanced HIV disease. 
• So if HIV patient has low CD 4 count there is high chance of 
thyroid dysfunction. 
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• 57.89 % of those with thyroid dysfunction had hemoglobin less 
than 9 g/dl   chi square value – 14.199 and  p value- 0.003 
statistically significant. 
• Pallor and low haemoglobin is associated with thyroid dysfunction 
and hence HIV disease patients with anaemia should be screened 
for thyroid dysfunction. 
• Hence thyroid function screening may be done in newly diagnosed 
HIV  patients with  –CD4  counts <200 / µL or  WHO clinical 
stage 3 or 4 or if patient has  hemoglobin <9 g/dl or pallor. 
• Thyroid function abnormalities need to be detected earlier even at 
subclinical level especially before starting ART  in patients with 
advanced HIV disease as ART initiation itself can make the patient 
with subclinical hypothyroidism to go in for a frank 
hypothyroidism and those with hypothyroidism to severe 
hypothyroidism leading to increased morbidity. 
• So based on the findings of our study it is suggested that thyroid 
function screening be done in HIV patients with WHO clinical 
stage 3 or 4 or CD 4 count < 200/µl and also those with pallor 
clinically or Hemoglobin <9 g/dl. 
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ANNEXURE 
PROFORMA 
NAME:     AGE: 
SEX:      Patient ID : 
ADDRESS:     OCCUPATION: 
HISTORY: SYMPTOM PRESENTATION 
Chief complaints: 
HOPC: 
1)Weight loss :yes/no…….duration……..quantity:…… 
2) Headache, nasal discharge, ear discharge, cough: yes/no 
3)ORAL CAVITY: 
Splits at angle of the mouth:yes/no…….. Ulcers in mouth:yes/no……. 
Oral thrush:-yes/no…….duration……….. 
3)SKIN: 
Painful rash:yes/no……… duration…. 
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Pruritic lesion:yes/no………. Scaly itchy skin 
lesions:yes/no……….duration……. 
4)Fever:yes/no…….type……..duration………diuranal variation:……… 
5)Diarrhea/vomiting:yes/no….frequency…quality….quantity: …….. 
6)Cough, dyspnoea:yes/no……..type…….variation…….duration……. 
7)Painful anogenital / orolabial wound: yes/ no……..duration………. 
8)Retrosternal pain/dysphagia : yes/no……….duration……… 
9)Visual symptoms: Diminished/blurring of vision: yes/no…… 
10)Headache: yes/no….type….duration... confusion: yes/no……..  
Drowsiness: yes/no……..Behavioural change:……. 
Muscular weakness: yes/no……… Numbness/tingling: yes/no……… 
Past history: PTB: yes/no…. h/o:Previous treatment for CA: yes/no….. 
h/o CNS infections: yes/no… h/o recurrant oral ulcerations: yes/no… 
h/o diarrhea: yes/no…….duration…….frequency…….. 
Drug history: 
Personal history: 
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Menstrual history: 
Bowel/Bladder:normal/altered  ……. 
Specific history(thyroid): 
fatigue: irritability: weakness: heat intolerance:constipation: sweating 
cold intolerance: palpitations:slowed mentation: tremors: 
hoarseness of voice: muscle weakness: 
Clinical examination: 
BMI: 
Thyroid examination: 
Slow cerebration: Attention span: 
Slow movement : Tremors: 
Slowing of ankle jerk: Tachycardia: 
Weight gain: Weight loss: 
Thyroid local examination: 
Eye examination:                                Skin examination: 
Nails:                                                     Lymph nodes: 
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Oral thrush 
Pallor-    icterus-    cyanosis-   clubbing-    pedal edema- 
Pulse:.. BP… Temperature….- R.R…. 
CHEST: 
Inspection: Shape/symmetry: Trachea-       Apical impulse- 
Palpation:  Chest movements:              Chest measurements: 
Palpable rhonchi/crackles: 
Percussion: 
Auscultation: Breath sound                 Added sounds: 
CVS: JVP:……     Apical impulse 
S1……S2………..S3………S4……….      Murmurs:…… 
Abdomen: 
Organomegaly:+/-            Free fluid:               Mass: 
CNS:        higher mental functions: 
neck stiffness/kernig’s:                               focal deficits: 
WHO clinical stage:( 2/3/4)- 
Investigations:CD4- 
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Immunological stage: 
CBC 
ECG 
LFT 
RFT 
Chest x-ray- 
THYROID: 
T3 ….    T4….    TSH…. 
 body fluid analysis(if indicated): Sputum: (when indicated) 
Stool exam: (when indicated) Urine microscopy: 
Lymph node fnac/biopsy: (when indicated) 
Neuro-imaging(when indicated) 
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CONSENT FORM 
Yourself Mr./Mrs./Ms……………………………………………….…… 
are being asked to be a participant in the research study titled “STUDY 
OF THYROID FUNCTION ABNORMALITIES IN NEWLY   
DIAGNOSED HIV PATIENTS” in CMC Hospital, Coimbatore, 
conducted by Dr.Dhanya.S.Kumar Post Graduate Student in the 
Department of General Medicine, Coimbatore Medical College. You 
satisfy eligibility as per the inclusion criteria. You can ask any question 
you may have before agreeing to participate. 
Research Being Done 
“STUDY OF THYROID FUNCTION ABNORMALITIES IN NEWLY   
DIAGNOSED HIV PATIENTS”  in Coimbatore Medical College 
Purpose of Research 
(1)  To study thyroid function abnormalities in newly diagnosed HIV 
 patients.  
(2)    To find out relation between thyroid function abnormalities and  
 severity of   illness in HIV infected patients 
 
 
 
120 
 
Procedures involved 
The research includes detailed clinical examination including medical 
history, physical examination. Laboratory investigations including HIV 
ELISA test , thyroid function tests,  complete haemogram, CD4 count. 
Decline from Participation 
You have the option to decline from participation in the study existing 
protocol for your condition. 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
Authorization to publish Results 
Results of the study may be published for scientific purposes and/or 
presented to scientific groups; however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me, and I may ask questions at any time. 
  
-------------------------------    ------------------------------- 
Signature /Left thumb impression      Date 
(Volunteer) 
--------------------------------    -------------------------------- 
Signature of witness        Date 
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xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :        taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; kfg;ngW kUj;Jt 
Jiwapy; gl;l gapYk; khztp mth;fs; nkw;bfhs;Sk;  "vr;.I.tp 
nehahspfspy; ijuha;L gpur;rid" Fwpj;j Ma;tpy; bra;Kiw 
kw;Wk; midj;J tptu';fisa[k; nfl;Lf; bfhz;L vdJ 
re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpy; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :       ifbahg;gk; / nuif 
ehs; : 
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KEY TO MASTER CHART 
CONSTITU SYMP – CONSTITUTIONAL SYMPTOMS 
SYMP- Symptoms 
S/S – Signs and symptoms 
BMI -  Body Mass Index 
LN – lymph node 
HB – haemoglobin  
CXR-  chest X ray 
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MASTER CHART 
sl 
No
:  
Patient 
ID  AGE SEX 
CONSTIT
U SYMP 
SYSTEMI
C SYMP 
S/S of 
hypoth 
yroidism 
S/S of 
hyperth 
yroidism BMI 
GOI 
TRE 
PAL 
LOR LN 
ORAL 
CANDI 
DIASIS 
HB 
(g/dl
) CXR T3 T4 TSH CD4  
clinical 
diagnosis 
WHO 
clinica
l stage DIAGNOSIS 
1 10231 48 male present 
RS- 
cough 
sputum absent absent 19 no yes no yes 7.8 PT 54 6.8 9.8 28 
TB 
meningitis 4 hypothyroidism 
2 10239 58 female present 
CNS - 
seizures 
fever absent absent 23 no no no no 11 PT 153 5.6 1.85 200 
pulmonary 
TB 3 euthyroidism 
3 10246 33 female present 
RS- 
cough 
sputum absent absent 22 no yes no yes 9 
cons
olida
tion 98 6.5 3.7 298 
pneumonia
/ oral 
candidiasis  3 euthyroidism 
4 10694 38 female absent 
nail 
infection  absent absent 23.5 no no no yes 11 
norm
al 62 7 17.2 420 
r/c oral 
ulcer/ 
fungal nail 
inf 2 
subclinical  
hypothyroidism 
5 10693 40 male present 
skin 
lesion absent absent 24 no no no no 12.6 
norm
al 120 7.6 3.6 280 
herpes 
zoster 2 Euthyroidism 
6 10687 34 female present 
diarrhoe
a absent absent 19 no yes no no 8.6 
norm
al 128 6.8 4.2 294 
Cryptospor
idiosis 2 euthyroidism 
7 10688 30 female present 
RS- 
cough 
sputum absent absent 21 no no no no 12 
cons
olida
tion 134 6.2 2.8 340 
Pneumoco
ccal 
pneumonia 2 euthyroidism 
8 10690 40 male present 
RS- 
cough 
sputum absent absent 20 no yes no yes 10 
milia
ry TB 98 8.2 4.5 200 Miliary TB 3 euthyroidism 
9 10264 31 female absent 
oral 
candidias
is absent absent 24 no yes no yes 9.6 
norm
al 104 6.4 3.4 300 
oral 
candidiasis 2 euthyroidism 
10 10283 33 female present 
chronic 
diarrhoe
a absent absent 19 no yes no yes 8 
norm
al 73 5.2 7.8 145 
chronic 
diarrhoea 3 
subclinical  
hypothyroidism 
11 10351 48 male absent 
RS- 
cough 
sputum absent absent 22 no yes no no 9.2 PT 120 5.8 3.2 260 
pulmonary 
TB 3 euthyroidism 
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12 10347 52 female present 
RS- 
cough 
sputum absent absent 23 no no no yes 12 
PCP 
pneu
moni
a 68 6.98 3.33 192 
PCP 
pneumonia 4 euthyroidism 
13 10339 30 male absent 
skin 
lesion absent absent 22 no no no no 12.6 
kapo
si 
sarco
ma 142 5.4 3.8 380 
kaposi's 
sarcoma 2 euthyroidism 
14 10336 41 female present 
headach
e absent absent 23 no no no no 12 
norm
al 149 7.2 8.6 220 meningitis 3 
subclinical  
hypothyroidism 
15 10312 30 male present 
intestinal 
obstructi
on absent absent 24 no no no yes 12 
norm
al 140 6.7 4.4 264 
oral 
candidiasis 2 euthyroidism 
16 10642 32 female present 
oral 
candidias
is absent absent 18 no no no yes 13 
norm
al 40 5.4 3.2 124 
pulmonary 
TB 3 Low T3 
17 10650 33 male absent absent absent absent 24 no no yes no 12 
norm
al 76 7.4 2.4 424 
Persistent 
generalised 
lymphadeo
pathy 1 euthyroidism 
18 10659 52 female absent absent present absent 28 no yes no yes 12 
norm
al 50 8.87 8.9 350 
herpes 
zoster 2 hypothyroidism 
19 10666 40 male absent 
CNS- 
altered  
sensoriu
m absent absent 24 no no no yes 12 
norm
al 110 7.6 3.6 180 PMLE 3 euthyroidism 
20 10680 48 female present 
abdomin
al pain absent absent 20 no no no yes 12 
norm
al 132 7.2 2.2 120 
Abdominal
TB 4 euthyroidism 
21 10377 42 female absent 
abdomin
al pain absent present 22 no no no yes 13 
norm
al 176 15 0.3 212 
oral 
candidiasis 2 hyperthyroidism 
22 10370 38 female absent 
recurrent 
oral 
ulceratio
n absent absent 23 no no no yes 12.4 
norm
al 140 8.2 3.6 232 
oral 
candidiasis
/ rec oral 
ulceration 2 euthyroidism 
23 10364 30 male present 
RS- 
cough 
sputum absent absent 22 no yes no yes 10 
bron
chop
neu
moni
a 122 7.4 2.6 280 
pneumoco
ocal 
pneumonia
/candidiasi
s 2 euthyroidism 
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24 10359 33 female present dysphagia absent absent 17 no yes no yes 7.4 
norm
al 40 5.4 2.8 64 
esophageal 
candidiasis 4 Low T3 
25 10353 31 male present 
RS- cough 
sputum absent absent 24 no no no no 11 
b/l 
pneu
moni
a 130 8.7 8.3 360 
b/l staph 
pneumonia 3 
subclinical 
hypothyroidism 
26 10603 28 female present 
RS- cough 
sputum absent absent 18.6 no yes no no 10.2 PT 134 8 4.2 288 
pulmonary 
TB 3 euthyroidism 
27 10606 29 female present 
oral 
candidiasis absent absent 22 no no no yes 13 
norm
al 126 7.6 3.2 280 
oropharyn
geal 
candidiasis 2 euthyroidism 
28 10607 30 female present 
RS- cough 
sputum absent absent 20 no no no yes 10 
cons
olida
tion 120 7.8 3 280 
Pneumoco
ccal 
pneumonia 2 euthyroidism 
29 10633 42 male present cough absent absent 20 no yes no yes 9 
PCP 
pneu
moni
a 72 5.6 6.2 94 
PCP 
pneumonia 4 
subclinical 
hypothyroidism 
30 10623 38 female present 
CNS- 
headache absent absent 22 no yes no yes 10.2 
norm
al 154 6.7 3.6 132 meningitis 3 euthyroidism 
31 10410 39 male present nil absent absent 22 no yes no yes 8.8 
norm
al 142 5.8 3.33 360 
oral 
candidiasis 2 euthyroidism 
32 10404 56 female present 
cough and 
neck  
swelling absent absent 18 no  yes yes yes 6 PT 50 6.2 9.4 85 
Disseminat
ed 
tuberculosi
s 4 hypothyroidism 
33 10409 30 female absent 
oral 
candidiasis absent absent 22 no  no no yes 13 
norm
al 122 8 2.8 320 
oropharyn
geal 
candidiasis 2 Euthyroidism 
34 10392 36 male absent 
RS- cough 
sputum absent absent 19 no yes no yes 9.6 PT 150 7.2 4.4 220 
pulmonary 
TB 3 euthyroidism 
35 10383 32 female absent 
head ache 
eye pain absent absent 21 no yes yes yes 9 
norm
al 99 6.5 8 99 
CMV 
retinitis 4 
subclinical 
hypothyroidism 
36 10515 42 male absent skin lesion absent absent 23.5 no no no no 13 
norm
al 88 7.2 4.2 304 
seborrheic 
dermatitis 2 euthyroidism 
37 10519 34 female absent absent absent absent 22.5 no no no no 12 
norm
al 110 7.6 3.6 388 
asymptom
atic 1 euthyroidism 
38 10536 38 male present cough  absent absent 21 no yes no no 8.5 PT 52 6.7 8.9 300 
pulmonary 
TB 3 hypothyroidism 
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39 10593 46 male absent 
severe 
weight loss absent absent 18 no yes no no 7.8 
norm
al 154 7.2 9 320 
severe 
weight loss 3 
subclinical 
hypothyroidism 
40 10597 51 female absent 
CNS - 
altered 
sensorium absent absent 24 no yes no no 9 
norm
al 69 7.2 8 280 
HIV 
encephalo
pathy 4 
subclinical 
hypothyroidism 
41 10511 58 male present 
CNS- 
headache/
seisure absent absent 21 no yes yes no 9.2 
norm
al 64 5.6 4 88 
CNS 
Toxoplasm
osis 4 euthyroidism 
42 10476 35 female present skin lesion absent absent 23 no no no no 14 
norm
al 110 6.4 4 212 
herpes 
zoster 2 euthyroidism 
43 10465 44 female present 
 
nephropat
hy absent absent 23 no yes no yes 8 
cardi
ome
galy 94 7.3 7.3 138 
HIV 
associated 
nephropat
hy 4 
subclinical 
hypothyroidism 
44 10458 31 female present 
 CNS 
headache 
LOC absent absent 24 no no no yes 12 
norm
al 42 11.3 
43.8
6 90 
CNS 
Toxoplasm
osis 4 hypothyroidism 
45 10448 52 male absent absent absent absent 24 no no no no 14 
norm
al 140 6.9 4.2 276 
asymptom
atic 1 euthyroidism 
46 10447 34 female present absent absent absent 22 no no yes no 13.2 
norm
al 132 8.2 4 340 
Persistent 
generalised 
lymphadeo
pathy 1 euthyroidism 
47 10443 32 female present 
cough  
sputum absent absent 22 no yes no yes 9.2 
PCP 
pneu
moni
a 42 3.4 10 186 
PCP 
pneumonia 4 Hypothyroidism 
48 10438 45 male present 
headache 
/seizure absent absent 21 no no no yes 12.4 
norm
al 48.5 10 3.6 104 
TB 
meningitis 4 euthyroidism 
49 10424 43 female present 
RS- cough 
sputum absent absent 20 no yes no yes 8.8 PT 69 9.4 6.8 120 
pulmonary 
TB 3 
subclinical 
hypothyroidism 
50 10421 32 male present 
RS- cough 
sputum absent absent 23 no no no no 13.2 
cons
olida
tion 100 8.4 3.8 240 
bacterial 
pneumonia 4 euthyroidism 
 
 
